4 November 2025 - AstraZeneca Korea announced on Monday that the C5 complement inhibitor Ultomiris (ravulizumab) has been covered by national health insurance since Saturday for the “treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients with anti-aquaporin-4 (AQP-4) antibodies.”

Ultomiris is covered for NMOSD patients aged 18 years or older who are anti-aquaporin-4 (anti-AQP-4) antibody-positive and have an Expanded Disability Status Scale (EDSS) score of 7 or lower at the time of Ultomiris administration.

Read Korea Biomedical Review article